Probiotic-based therapy for TIIDM and obesity-associated metabolic deficits: Probiotic VSL#3 increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 8/January/2019, 11.45 pm